The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Flagged first, then by citations
1 of the 94 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 1,003
Krug, B., Jay, N. D., Harutyunyan, A. S., Deshmukh, S., Marchione, D. M., Guilhamon, P., Bertrand, K. C., Mikael, L. G., McConechy, M. K., Chen, C. C. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.004 · Cited by 245
Intratumoral Heterogeneity: More Than Just Mutations
Hinohara, K., & Polyák, K. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.03.003 · Cited by 241
Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia
Cuellar, T. L., Herzner, A., Zhang, X., Goyal, Y., Watanabe, C. K., Friedman, B. A., Janakiraman, V., Durinck, S., Stinson, J., Arnott, D. P., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201612160 · Cited by 241
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 233
Identification of tumor antigens with immunopeptidomics
Chong, C., Coukos, G., & Bassani-Sternberg, M. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01038-8 · Cited by 232
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling, E. A., Wang, J. H., Gong, F., Wu, W., Neill, N. J., Kim, I. S., Tyagi, S., Orellana, M. C., Kurley, S. J., Domínguez-Vidaña, R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.031 · Cited by 227
Self-citationVitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine
Liu, M., Ohtani, H., Zhou, W., Ørskov, A. D., Charlet, J., Zhang, Y. W., Shen, H., Baylin, S. B., Liang, G., Grønbæk, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612262113 · Cited by 225
Self-citationTargeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 223
Self-citationStomper, J., Rotondo, J. C., Greve, G., & Lübbert, M. (2021) · Leukemia · doi:10.1038/s41375-021-01218-0 · Cited by 224
Merlevede, J., Droin, N. M., Qin, T., Meldi, K. M., Yoshida, K., Morabito, M., Chautard, É., Auboeuf, D., Fenaux, P., Braun, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10767 · Cited by 225
Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein
Lei, Y., Zhang, X., Su, J., Jeong, M., Gundry, M. C., Huang, Y.-H., Zhou, Y., Li, W., & Goodell, M. A. (2017) · Nature Communications · doi:10.1038/ncomms16026 · Cited by 218
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
Turcan, Ş., Makarov, V., Taranda, J., Wang, Y., Fabius, A. W. M., Wu, W., Zheng, Y., El-Amine, N., Haddock, S., Nanjangud, G. J., et al. (2017) · Nature Genetics · doi:10.1038/s41588-017-0001-z · Cited by 221
Self-citationVaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 223
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 219
Self-citationPfannstiel, C., Strissel, P. L., Chiappinelli, K. B., Sikic, D., Wach, S., Wirtz, R. M., Wullweber, A., Taubert, H. W., Breyer, J., Otto, W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0758 · Cited by 213
Self-citationImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Co-option of endogenous viral sequences for host cell function
Frank, J. A., & Feschotte, C. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.07.021 · Cited by 207
Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma
Parasramka, M. A., Maji, S., Matsuda, A., Yan, I. K., & Patel, T. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.004 · Cited by 212
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Nathanson, T., Ahuja, A., Rubinsteyn, A., Aksoy, B. A., Hellmann, M. D., Miao, D., Allen, E. M. V., Merghoub, T., Wolchok, J. D., Snyder, A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0019 · Cited by 211
Self-citationCurrent Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 209
Epigenetics in cancer therapy and nanomedicine
Roberti, A., Valdes, A. F., Torrecillas, R., Fraga, M. F., & Fernández, A. F. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0675-4 · Cited by 216
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 207
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis
Chen, R. E., Ishak, C. A., & Carvalho, D. D. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0506 · Cited by 213
How to stomach an epigenetic insult: the gastric cancer epigenome
Padmanabhan, N., Ushijima, T., & Tan, P. B. O. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.53 · Cited by 209
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Liu, T., Qin, S., Zhuang, Y., Liu, D., Lu, W., Kalari, K. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97924 · Cited by 203
Kaluscha, S., Domcke, S., Wirbelauer, C., Stadler, M. B., Durdu, S., Burger, L., & Schübeler, D. (2022) · Nature Genetics · doi:10.1038/s41588-022-01241-6 · Cited by 228
Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential
Kazanets, A., Shorstova, T., Hilmi, K., Marques, M., & Witcher, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.04.001 · Cited by 203
DNMT1: A key drug target in triple-negative breast cancer
Wong, K. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.010 · Cited by 200
Endogenous retroviruses promote homeostatic and inflammatory responses to the microbiota
Lima-Junior, D. S., Krishnamurthy, S. R., Bouladoux, N. J., Collins, N., Han, S., Chen, Y. E., Constantinides, M. G., Link, V. M., Lim, A. I., Enamorado, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.020 · Cited by 204
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 208
Function of HNRNPC in breast cancer cells by controlling the dsRNA‐induced interferon response
Wu, Y., Zhao, W., Liu, Y., Tan, X., Li, X., Zou, Q., Xiao, Z., Xu, H., Wang, Y., & Yang, X. (2018) · The EMBO Journal · doi:10.15252/embj.201899017 · Cited by 199
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Segovia, C., José‐Eneriz, E. S., Munera-Maravilla, E., Martínez‐Fernández, M., Gárate, L., Miranda, E., Vilas‐Zornoza, A., Lodewijk, I., Rubio, C., Segrelles, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0499-y · Cited by 191
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs
Rañoa, D. R. E., Parekh, A. D., Pitroda, S. P., Huang, X., Darga, T. E., Wong, A., Huang, L., Andrade, J., Staley, J. P., Satoh, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8420 · Cited by 184
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00503-z · Cited by 190
Daver, N. G., Boddu, P. C., Garcia‐Manero, G., Yadav, S. S., Sharma, P., Allison, J. P., & Kantarjian, H. M. (2018) · Leukemia · doi:10.1038/s41375-018-0070-8 · Cited by 183
Silencing and Transcriptional Regulation of Endogenous Retroviruses: An Overview
Geis, F. K., & Goff, S. P. (2020) · Viruses · doi:10.3390/v12080884 · Cited by 188
Qu, K., Zaba, L. C., Satpathy, A. T., Giresi, P. G., Li, R., Jin, Y., Armstrong, R. J., Chen, J., Schmitt, N., Rahbar, Z., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.008 · Cited by 175
Enhancing in situ cancer vaccines using delivery technologies
Gong, N., Alameh, M., El-Mayta, R. D., Xue, L., Weissman, D., & Mitchell, M. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00974-9 · Cited by 197
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements
Shah, N. M., Jang, H. J., Liang, Y., Maeng, J. H., Tzeng, S.-C., Wu, A., Basri, N. L., Qu, X., Fan, C., Li, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01349-3 · Cited by 175
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
Diesch, J., Zwick, A., Garz, A.-K., Palau, A., Buschbeck, M., & Götze, K. S. S. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0237-y · Cited by 177
IAP antagonists induce anti-tumor immunity in multiple myeloma
Chesi, M., Mirza, N. N., Garbitt, V. M., Sharik, M. E., Dueck, A. C., Asmann, Y. W., Akhmetzyanova, I., Kosiorek, H., Calcinotto, A., Riggs, D. L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4229 · Cited by 171
The Epigenetic Hallmarks of Cancer
Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 202
Self-citationNiu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Self-citationZhou, X., Singh, M., Sanz Santos, G., Guerlavais, V., Carvajal, L. A., Aivado, M., Zhan, Y., Oliveira, M. M. S., Westerberg, L. S., Annis, D. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1741 · Cited by 169
An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences
Ishak, C. A., Marshall, A. E., Passos, D. T., White, C. R., Kim, S. J., Cecchini, M. J., Ferwati, S., MacDonald, W. A., Howlett, C. J., Welch, I. D., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.021 · Cited by 167
Coscia, F., Lengyel, E. R., Duraiswamy, J., Ashcroft, B., Bassani‐Sternberg, M., Wierer, M., Johnson, A., Wroblewski, K., MONTAG, A. G., Yamada, S. D., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.065 · Cited by 168
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Luchtel, R. A., Bhagat, T. D., Pradhan, K., Jacobs, W. R., Levine, M., Verma, A. K., & Shenoy, N. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908158117 · Cited by 171
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Micevic, G., Theodosakis, N., & Bosenberg, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0332-8 · Cited by 171
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Kong, X., Chen, J., Xie, W., Brown, S. M., Cai, Y., Wu, K., Fan, D., Nie, Y., Yegnasubramanian, S., Tiedemann, R. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.003 · Cited by 166
Self-citationCombining epigenetic and immune therapy to overcome cancer resistance
Gomez, S., Tabernacki, T., Kobyra, J. A., Roberts, P. A., & Chiappinelli, K. B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.019 · Cited by 170
Self-citationDNA Hypomethylating Drugs in Cancer TherapyPreprint
Sato, T., Issa, J. J., & Kropf, P. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026948 · Cited by 169
The HUSH complex is a gatekeeper of type I interferon through epigenetic regulation of LINE-1s
Tunbak, H., Enriquez-Gasca, R., Tie, C. H. C., Gould, P. A., Mlcochova, P., Gupta, R. K., Fernandes, L., Holt, J., van der Veen, A. G., Giampazolias, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19170-5 · Cited by 162
Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors
Leruste, A., Tosello, J., Ramos, R. N., Tauziède‐Espariat, A., Brohard, S., Han, Z., Beccaria, K., Andrianteranagna, M. J. D. D., Caudana, P., Nikolić, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.008 · Cited by 168
Epigenetics in renal cell cancer: mechanisms and clinical applications
Joosten, S. C., Smits, K. M., Aarts, M. J. B., Melotte, V., Koch, A., Tjan‐Heijnen, V. C. G., & van Engeland, M. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0023-z · Cited by 166
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases
Jiang, J., Zhao, M., Chang, C. C.-C., Wu, H., & Lu, Q. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08798-2 · Cited by 166
Clinical and biological effects of demethylating agents on solid tumours – A systematic review
Linnekamp, J. F., Butter, R., Spijker, R., Medema, J. P., & van Laarhoven, H. W. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.004 · Cited by 159
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Mbofung, R. M., McKenzie, J. A., Malu, S., Zhang, M., Peng, W., Liu, C., Kuiatse, I., Tieu, T., Williams, L., Devi, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00449-z · Cited by 159
Myelodysplastic syndromes current treatment algorithm 2018
Steensma, D. P. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0085-4 · Cited by 153
Bugide, S., Green, M. R., & Wajapeyee, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802691115 · Cited by 158
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity
Elewaut, A., Estivill, G., Bayerl, F., Castillon, L., Novatchkova, M., Pottendorfer, E., Hoffmann-Haas, L., Schönlein, M., Nguyễn, T. C. B., Lauss, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08257-4 · Cited by 167
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
Lee, J. B., Khan, D. H., Hurren, R., Xu, M., Na, Y., Kang, H., Mirali, S., Wang, X., Gronda, M., Jitkova, Y., et al. (2021) · Blood · doi:10.1182/blood.2020009081 · Cited by 165
Endogenous retroviruses in the origins and treatment of cancer
Jansz, N., & Faulkner, G. J. (2021) · Genome biology · doi:10.1186/s13059-021-02357-4 · Cited by 158
Losing DNA methylation at repetitive elements and breaking bad
Pappalardo, X. G., & Barra, V. (2021) · Epigenetics & Chromatin · doi:10.1186/s13072-021-00400-z · Cited by 165
The promise of epigenetic therapy: reprogramming the cancer epigenome
Kelly, A. D., & Issa, J. J. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.03.015 · Cited by 160
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation
Zeiser, R., & Vago, L. (2018) · Blood · doi:10.1182/blood-2018-10-846824 · Cited by 162
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
Davies, A., Zoubeidi, A., Beltran, H., & Selth, L. A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0225 · Cited by 170
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Achard, C., Surendran, A., Wedge, M.-È., Ungerechts, G., Bell, J. C., & Ilkow, C. S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.020 · Cited by 163
Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer
Deblois, G., Tonekaboni, S. A. M., Grillo, G., Martínez, C., Kao, Y. I., Tai, F., Ettayebi, I., Fortier, A.-M., Savage, P., Fedor, A. N., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1493 · Cited by 160
Feng, X., Tubbs, A., Zhang, C., Tang, M., Sridharan, S., Wang, C., Jiang, D., Su, D., Zhang, H., Chen, Z., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104036 · Cited by 152
Hurst, T. P., & Magiorkinis, G. (2017) · Viruses · doi:10.3390/v9060130 · Cited by 154
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Hubert, M., Gobbini, É., Couillault, C., Manh, T. V., Doffin, A., Berthet, J., Rodriguez, C., Ollion, V., Kielbassa, J., Sajous, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3942 · Cited by 158
The role of epigenetic modifications in drug resistance and treatment of breast cancer
Fath, M. K., Azargoonjahromi, A., Kiani, A., Jalalifar, F., Osati, P., Oryani, M. A., Shakeri, F., Nasirzadeh, F., Khalesi, B., Nabi‐Afjadi, M., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00344-6 · Cited by 153
Nguyen, E. M., Taniguchi, H., Chan, J. M., Zhan, Y. A., Chen, X., Qiu, J. J., de Stanchina, E., Allaj, V., Shah, N., Uddin, F. Z., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.014 · Cited by 144
Selecting Target Antigens for Cancer Vaccine Development
Buonaguro, L., & Tagliamonte, M. (2020) · Vaccines · doi:10.3390/vaccines8040615 · Cited by 150
Bruand, M., Barras, D., Mina, M., Ghisoni, E., Morotti, M., Lanitis, E., Fahr, N., Desbuisson, M., Grimm, A. J., Zhang, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109412 · Cited by 146
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Jiang, Y., Zhang, H., Wang, J., Chen, J., Guo, Z., Liu, Y., & Hua, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01405-9 · Cited by 151
Hematopoietic aging promotes cancer by fueling IL-1⍺–driven emergency myelopoiesis
Park, M. D., Bérichel, J. L., Hamon, P., Wilk, C. M., Belabed, M., Yatim, N., Saffon, A., Boumelha, J., Falcomatà, C., Tepper, A., et al. (2024) · Science · doi:10.1126/science.adn0327 · Cited by 149
DNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Wylie, B., Macri, C., Mintern, J. D., & Waithman, J. C. (2019) · Cancers · doi:10.3390/cancers11040521 · Cited by 149
Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer
Kim, J. Y., Choi, J. K., & Jung, H. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00907-4 · Cited by 141
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 145
Our Conflict with Transposable Elements and Its Implications for Human Disease
Burns, K. H. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032633 · Cited by 137
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 139
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Maxwell, M. B., Hom, M. S., Yi, J., Li, S., Rivera, S. A., Yu, J., Burns, M. J., McRae, H. M., Stevenson, B. T., Coakley, K. E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.025 · Cited by 147
RIG-I activation is critical for responsiveness to checkpoint blockade
Heidegger, S. M., Wintges, A., Stritzke, F., Bek, S., Steiger, K., Koenig, P.-A., Göttert, S., Engleitner, T., Öllinger, R., Nedelko, T., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8943 · Cited by 136
Self-citationTargeting the tumor microenvironment in renal cell cancer biology and therapy
Heidegger, I., Pircher, A., & Pichler, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00490 · Cited by 133
Unnikrishnan, A., Papaemmanuil, E., Beck, D., Deshpande, N., Verma, A., Kumari, A., Woll, P. S., Richards, L. A., Knezevic, K., Chandrakanthan, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.067 · Cited by 137
Shallis, R. M., Gale, R. P., Lazarus, H. M., Roberts, K. B., Xu, M. L., Seropian, S., Gore, S. D., & Podoltsev, N. A. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100773 · Cited by 133
Zhou, F., Li, M., Wei, Y., Lin, K., Lu, Y., Shen, J., Johanning, G. L., & Wang‐Johanning, F. (2016) · Oncotarget · doi:10.18632/oncotarget.11455 · Cited by 131
Advances in epigenetic therapeutics with focus on solid tumors
Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 135
Structures, functions and adaptations of the human LINE-1 ORF2 protein
Baldwin, E. T., van Eeuwen, T., Hoyos, D., Zalevsky, A. O., Tchesnokov, E. P., Sánchez, R., Miller, B. D., Stefano, L. H. D., Ruiz, F. X., Hancock, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06947-z · Cited by 145
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
Majchrzak‐Celińska, A., Szoszkiewicz, A., & Szoszkiewicz, M. (2021) · Genes · doi:10.3390/genes12020208 · Cited by 135
Ohtani, H., Liu, M., Zhou, W., Liang, G., & Jones, P. A. (2018) · Genome Research · doi:10.1101/gr.234229.118 · Cited by 132
Liu, M., Thomas, S. L., DeWitt, A. K., Zhou, W., Madaj, Z. B., Ohtani, H., Baylin, S. B., Liang, G., & Jones, P. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3953 · Cited by 127
Self-citationAberrant DNA Methylation in Colorectal Cancer: What Should We Target?
Tse, J. W. T., Jenkins, L. J., Chionh, F. J. M., & Mariadason, J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.003 · Cited by 125
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
